First-ever Combination of Two Immuno-Oncology Agents for Metastatic Melanoma Approved by Health Canada

Bristol-Myers Squibb receives approval from Health Canada for the OPDIVO® + YERVOY® Regimen for unresectable or metastatic melanoma OPDIVO® + YERVOY® Regimen demonstrates the potential of targeting distinct and complementary immune pathways at the same time